Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb

• 产品编号：CST-2243L      品牌：CST       原厂货号：2243L
• 产品分类：抗体 > 一抗 > 磷酸化抗体
• 应用分类：

描述：

磷酸化HER2/ErbB2 (Tyr1221/1222) (6B12) 兔单抗仅在Tyr1221/1222被磷酸化时才能检测到内源性ErbB2的存在。本抗体不与激活的ErbB家族其它成员以及其它酪氨酸位点磷酸化的蛋白发生交叉反应。单克隆抗体通过用多肽免疫动物得到，该磷酸化多肽是根据人的ErbB2蛋白Tyr1221/1222附近的氨基酸序列合成的。

原癌基因ErbB2 (HER2)编码185kDa的受体样跨膜糖蛋白，该蛋白具有固有的酪氨酸激酶的活性 (1)。ErbB2的配体目前尚不清楚，但在高表达的ErbB2与其它ErbB家族成员形成异源二聚体时，即使缺少配体，其酶活性仍能被激活(2)。将近40%的人类乳腺癌中能够检测到ErbB2基因的扩增及其产物的过量表达。泛素连接酶c-Cbl结合在ErbB2的Tyr1112上能够导致ErbB2聚泛素化并促进其降解(4)。ErbB2是乳腺癌等多种癌肿的关键治疗靶点，通过c-Cbl介导的蛋白水解途径靶向调控ErbB2的降解是一种潜在的治疗手段。磷酸化ErbB2的激酶位点Tyr877（同源于pp60c-Src 的Tyr416）能调控ErbB2的生物活性。ErbB2的自磷酸化位点是Tyr1248和 Tyr1221/1222，这些位点的磷酸化将ErbB2与Ras-Raf-MAP激酶的信号转导途径联系起来(1,5)。

1. Muthuswamy, S.K. et al. (1999) Mol Cell Biol 19, 6845-57.
2. Qian, X. et al. (1994) Proc Natl Acad Sci USA 91, 1500-4.
3. Dittadi, R. and Gion, M. (2000) J Natl Cancer Inst 92, 1443-4.
4. Klapper, L.N. et al. (2000) Cancer Res 60, 3384-8.
5. Kwon, Y.K. et al. (1997) J Neurosci 17, 8293-9.

原厂资料：

Specificity / Sensitivity

Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb detects endogenous levels of ErbB2 only when phosphorylated at tyrosines 1221/1222. The antibody does not detect other activated Erb family members or other tyrosine-phosphorylated proteins.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding tyrosines 1221/1222 of human ErbB2 protein.

Background

The ErbB2 (HER2) proto-oncogene encodes a 185 kDa transmembrane, receptor-like glycoprotein with intrinsic tyrosine kinase activity (1). While ErbB2 lacks an identified ligand, ErbB2 kinase activity can be activated in the absence of a ligand when overexpressed and through heteromeric associations with other ErbB family members (2). Amplification of the ErbB2 gene and overexpression of its product are detected in almost 40% of human breast cancers (3). Binding of the c-Cbl ubiquitin ligase to ErbB2 at Tyr1112 leads to ErbB2 poly-ubiquitination and enhances degradation of this kinase (4). ErbB2 is a key therapeutic target in the treatment of breast cancer and other carcinomas and targeting the regulation of ErbB2 degradation by the c-Cbl-regulated proteolytic pathway is one potential therapeutic strategy. Phosphorylation of the kinase domain residue Tyr877 of ErbB2 (homologous to Tyr416 of pp60c-Src) may be involved in regulating ErbB2 biological activity. The major autophosphorylation sites in ErbB2 are Tyr1248 and Tyr1221/1222; phosphorylation of these sites couples ErbB2 to the Ras-Raf-MAP kinase signal transduction pathway (1,5).

1. Muthuswamy, S.K. et al. (1999) Mol Cell Biol 19, 6845-57.
2. Qian, X. et al. (1994) Proc Natl Acad Sci USA 91, 1500-4.
3. Dittadi, R. and Gion, M. (2000) J Natl Cancer Inst 92, 1443-4.
4. Klapper, L.N. et al. (2000) Cancer Res 60, 3384-8.
5. Kwon, Y.K. et al. (1997) J Neurosci 17, 8293-9.

注意事项：

For Research Use Only. Not For Use In Diagnostic Procedures.

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150
mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02%
sodium azide. Store at –20°C. Do not aliquot the antibody